 DUBLIN, Ireland, Feb. 11, 2021 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA, a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today reported financial results for the fourth quarter and full year 2020. In addition, the Company provided 2021 financial guidance and an update on its RD programs. 